Effects of L-carnitine supplementation on the quality of life in diabetic patients with muscle cramps
|
|
- Philip Crawford
- 5 years ago
- Views:
Transcription
1 Original doi: /endocrj.ej Effects of L-carnitine supplementation on the quality of life in diabetic patients with muscle cramps Ayumi Imbe, Keiji Tanimoto, Yuiko Inaba, Satoshi Sakai, Kanako Shishikura, Hisashi Imbe, Yoshimi Tanimoto, Jungo Terasaki, Akihisa Imagawa and Toshiaki Hanafusa Department of Internal Medicine (I), Osaka Medical College, Takatsuki, Osaka , Japan Abstract. Diabetic patients often suffer from muscle cramps. This study aimed to compare the quality of life (QOL) of diabetic patients with and without muscle cramps and to investigate the effect of L-carnitine supplementation in diabetic patients with muscle cramps. A total of 91 patients with diabetes were enrolled in this study: 69 patients with muscle cramps and 22 patients without muscle cramps. Muscle cramps and QOL were evaluated using the muscle cramp questionnaire and the Short Form 36 health survey version 2 (SF-36), respectively. Clinical characteristics were compared between diabetic patients with and without muscle cramps. In the prospective portion of the study, 25 diabetic patients with muscle cramps received L-carnitine supplementation (600 mg/day orally) for 4 months. The questionnaires were administered before and after supplementation. The SF-36 scores in diabetic patients with muscle cramps were lower than those in patients without muscle cramps on the subscales of physical function, role physical, bodily pain, vitality, general health, and social function. In the 25 patients with muscle cramps who received L-carnitine supplementation, the monthly frequency of muscle cramps and Wong- Baker FACES Pain Rating Scale scores were significantly decreased. Scores on the following SF-36 subscales improved after L-carnitine supplementation: body pain, vitality, social function, and role emotional. This study demonstrated that muscle cramps decrease the QOL in patients with diabetes, and L-carnitine supplementation may improve the QOL by reducing the frequency and severity of muscle cramps in these patients. Key words: Quality of life, Levocarnitine, Muscle cramp, Diabetes mellitus MUSCLE CRAMPS are a common symptom of painful contractions of a muscle group and are sometimes disabling [1]. Certain physical activities and medical conditions, such as exercise, hepatic and renal dysfunction, and polyneuropathy due to neurological conditions or diabetes mellitus, can cause muscle cramps [1]. Muscle cramps commonly occur in patients with cirrhosis and those undergoing hemodialysis [2, 3]. Some reports indicate that approximately 60% of patients with diabetes have experienced muscle cramps and that the pain they experience is more severe than that experienced by healthy people [1, 4]. Muscle cramps are thus speculated to impair QOL in patients with diabetes. The Short Form 36 Health Survey version 2 (SF-36) is a tool for evaluation of QOL and has been commonly Submitted Oct. 4, 2017; Accepted Jan. 26, 2018 as EJ Released online in J-STAGE as advance publication Mar. 6, 2018 Correspondence to: Keiji Tanimoto, 2-7 Daigaku-machi, Takatsuki, Osaka , Japan. in1120@osaka-med.ac.jp used in large population studies and clinical studies [5, 6]. In the Australian Diabetes, Obesity and Lifestyle Study, which was a population-based study of around 11,000 people, the SF-36 score in patients previously diagnosed with diabetes was significantly lower than that in individuals with normal glucose tolerance [7]. In a Malaysian study, type 2 diabetes mellitus patients with glycosylated hemoglobin (HbA1c) levels >7.5% (indicating poor glycemic control) had lower SF-36 scores than those with HbA1c levels 7.5% [8]. The SF-36, a short self-administered questionnaire used to assess general health status, has been cross-culturally adapted for use in Japanese patients, and has a high degree of acceptability and data quality [9, 10]. The Japanese version of the SF-36 was translated, adapted, and validated from the American English version by Fukuhara et al., whose results confirmed the reliability and equivalence of both the Japanese and American versions [9, 10]. Muscle cramps are often self-limiting and can usually be managed without professional medical treatment; The Japan Endocrine Society
2 2 Imbe et al. however, pharmacotherapy may be needed when the symptoms are persistent and disabling. Commonly used medications for the treatment of muscle cramps include B-complex vitamins, diltiazem, carbamazepine, mexiletine, and Shakuyaku-kanzo-to [1]. A recent study revealed that L-carnitine supplementation reduces muscle cramps in patients undergoing hemodialysis [3]. L-carnitine has also been shown to alleviate muscle weakness and aches, and decrease the visual analog pain scale score in patients with cirrhosis [2]. Carnitine is associated with the import of long-chain fatty acids into mitochondria for β-oxidation, which is the major source of energy for cardiac and skeletal muscle cells [11]. Previous reports revealed that the mean free L-carnitine level in the serum of diabetic patients with complications was lower than that in patients without complications [12]. In another report, L-carnitine levels were significantly lower in patients with neuropathic pain, especially when it was caused by diabetes [13]. In this study, we compared the clinical and patient characteristics of diabetic patients with and without muscle cramps. We also investigated the clinical effects of L-carnitine on muscle cramps and QOL in patients with diabetes. Materials and Methods Study design and participants A total of 91 patients with diabetes who visited the outpatient clinic of the Department of Diabetes, Metabolism, and Endocrinology at Osaka Medical College Hospital were enrolled in this study. Diabetes was diagnosed on the basis of the criteria proposed by the Japan Diabetes Society. All patients were treated with oral hypoglycemic agents and/or insulin for type 1 or type 2 diabetes. A total of 69 patients reported experiencing muscle cramps. Of these 69 patients, 25 who wished to receive L-carnitine supplementation were enrolled in the prospective portion of this study. In the prospective study, 300 mg levocarnitine chloride (L-carnitine tablets, Otsuka Pharmaceutical Co., Ltd, Japan) was prescribed to these patients twice a day (total dose of 600 mg/day) for 4 months. Four patients dropped out for economic reasons. Thus, 21 patients received L-carnitine supplementation for the entire 4 months. Before and after 4 months of L-carnitine supplementation, the cramp questionnaire and SF-36 were re-administered to these participants (Fig. 1). The diabetes treatment received by these patients could be changed to achieve better glycemic control at any time during the study. In the group of L-carnitine supplementation, three had already started receiving treatment for muscle cramps (one treated with Shakuyaku-kanozo-to, two treated with pregabalin) before the enrollment, and the treatment continued without change in dose throughout the study. Patient assessments All subjects completed the cramp questionnaire and the SF-36 questionnaire. The cramp questionnaire was a slightly modified version of a previously published questionnaire, and included a description of the frequency and severity of pain caused by muscle cramps according Fig. 1 The algorithm followed for inclusion in this current study.
3 Carnitine for muscle cramps in diabetes 3 to Wong-Baker FACES Pain Rating Scale that ranged from 0 (no hurt) to 5 (hurts worst) [14]. The Wong-Baker FACES Pain Rating Scale was originally published in Whaley & Wong s Nursing Care of Infants and Children. QOL was assessed using the Japanese version of the SF-36 [6]. The SF-36 comprises eight subscales: physical function (PF), role physical (RP), bodily pain (BP), vitality (VT), general health (GH), role emotional (RE), social function (SF), and mental health (MH). The score on each subscale ranges from 0 to 100 points, with higher scores indicating a better QOL. Blood samples were collected before and 4 months after L-carnitine supplementation to measure the levels of random blood glucose, HbA1c, and serum creatinine. Blood glucose and HbA1c levels were measured using hexokinase enzymatic analysis and high-performance liquid chromatography, respectively. Information on the other variables, of physical parameters (height and body weight) and complications, was extracted from the patients medical records. Body mass index (BMI) was calculated as body weight divided by height squared (kg/m 2 ). Statistical analyses All data were statistically analyzed using SPSS software, version 22 (SPSS Inc., Chicago, IL, USA). Descriptive statistics were expressed as mean and standard deviation, or range and median. The Mann Whitney U test was used for statistical analysis of patient characteristics and scores on the SF-36 subscales. The Wilcoxon signed rank test was used to compare parameters before and after L-carnitine supplementation. Compliance with ethical standards All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of the Osaka Medical College (No. 1256) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All participants in the study were provided clear information about the study and provided written informed consent. Results QOL of diabetic patients suffering muscle cramps As shown in Table 1, there were no differences in age, BMI, and HbA1c, blood glucose, and creatinine levels between the participants with and without muscle Table 1 Clinical characteristics of study participants Muscle cramp (+) Muscle cramp ( ) Number (Male/Female) 69 (31/38) 22 (11/11) Age (years) 67 ± ± 16 BMI (kg/m 2 ) 25.8 ± ± 4.7 Type of diabetes (type 1/type 2) 5/64 0/22 Blood glucose (mg/dl) ± ± 59.5 HbA1c (%) 9.4 ± ± 1.8 Creatinine (mg/dl) 0.86 ± ± 0.23 Frequency of muscle cramps per month 6.7 ( ) 0 Visual analogue scale for pain 3.8 (0 5) 0 Values are means ± standard deviation, median (min-max) or numbers of participants. indicates p < 0.05 compared to the value for the group with muscle cramps, calculated by Mann-Whitney test. Table 2 Participant scores on the SF-36 subscale Muscle cramp (+) Muscle cramp ( ) Physical Functioning 72.0 ± ± 17.1 Role Physical 67.0 ± ± 24.8 Bodily Pain 51.2 ± ± 22.4 General Health 43.3 ± ± 13.7 Vitality 48.7 ± ± 18.3 Social Functioning 70.3 ± ± 19.8 Role Emotional 70.5 ± ± 27.2 Mental Health 62.0 ± ± 18.0 Values are means ± standard deviation. indicates p < 0.05 compared to the value for the group with muscle cramps, calculated by Mann-Whitney test. cramps. Table 2 shows that the scores in participants with muscle cramps were significantly lower than those in the participants without muscle cramps on the subscales of PF, RP, BP, VT, GH, and SF. Impacts of insulin treatment and complications on QOL As shown in Table 3, no statistically significant differences were observed in all SF-36 subscale scores between the diabetic patients treated with and without insulin or those with and without diabetic nephropathy. The scores on PF, RP and RE were significantly lower in diabetic patients with diabetic retinopathy.
4 4 Imbe et al. Table 3 Participant scores on the SF-36 subscale Insulin (+) N = 23 Insulin ( ) N = 68 Retinopathy (+) N = 24 Retinopathy ( ) N = 50 Nephropathy (+) N = 34 Nephropathy ( ) N = 32 Physical Functioning 72.0 ± ± ± ± ± ± 17.2 Role Physical 65.8 ± ± ± ± ± ± 28.3 Bodily Pain 48.8 ± ± ± ± ± ± 27.8 General Health 44.3 ± ± ± ± ± ± 16.0 Vitality 48.4 ± ± ± ± ± ± 16.4 Social Functioning 70.1 ± ± ± ± ± ± 23.8 Role Emotional 77.9 ± ± ± ± ± ± 25.0 Mental Health 63.9 ± ± ± ± ± ± 21.0 Values are means ± standard deviation. indicates p < 0.05 compared to the value whether complication with retinopathy are existed or not, calculated using the Kruskal Wallis test. Table 4 Changes of clinical data in before and after carnitine supplementation Before carnitine supplementation (N = 21) After carnitine supplementation (N = 21) Blood glucose (mg/dl) ± ± 84.5 HbA1c (%) 7.8 ± ± 1.3 Creatinine (mg/dl) 1.1 ± ± 1.6 Frequency of muscle cramps per month Visual analogue scale pain score 4.0 ( ) 1.0 ( ) 4 (0 5) 3 (0 5) Values are means ± standard deviation, median (min max) or numbers of participants. indicates p < 0.05 compared to the value before carnitine supplementation, calculated using the Wilcoxon signed rank test. QOL by L-carnitine supplementation Table 4 shows that both the frequency of muscle cramps per month and score of Wong-Baker FACES Pain Rating scale decreased significantly 4 months after L-carnitine supplementation. It also resulted in a significant increase in blood glucose levels; but no significant changes in HbA1c and creatinine levels. Fig. 2 shows that the scores on the BP, VT, SF, and RE subscales of the SF-36 were significantly higher 4 months after L-carnitine supplementation compared to those before the supplementation. Discussion In the current study, 69 of the 91 patients with diabetes (75%) complained of muscle cramps and the scores of diabetic patients with muscle cramps on the SF-36 subscales of PF, RP, BP, GH, VT, and SF were significantly lower than the scores of diabetic patients without muscle cramps. We also revealed that L-carnitine supplementation resulted in a decrease in the frequency of muscle cramps and in the score of Wong-Baker FACES Pain Rating scale, and an increase in SF-36 scores. Our study revealed that percentage of suffering muscle cramps in the diabetic patients is similar to the previous report that the prevalence rates of muscle cramps are 39.5%, 57.5%, and 75.5% in healthy individuals, and patients with type 1 and type 2 diabetes, respectively [4]. Diabetic patients who experienced muscle cramps had impaired QOL according to our study. The scores of diabetic patients with muscle cramps on the SF-36 subscales of PF, RP, BP, GH, VT, and SF were significantly lower than the scores of diabetic patients without muscle cramps. The decrease in these scores reflects a decrease in the QOL of these patients as shown in previous studies. Painful diabetic neuropathy has a considerable impact on patients QOL because of the consequent sleep loss and reduction in energy levels [5, 15]. Cocito and colleagues revealed that pain worsened the QOL in patients with neuropathy [16]. Other studies revealed that scores of patients with painful diabetic polyneuropathy on all eight SF-36 subscales were lower than the scores of patients with non-painful diabetic polyneuropathy [17, 18].
5 Carnitine for muscle cramps in diabetes 5 Fig. 2 The effect of L-carnitine supplementation on the quality of life of diabetic patients with muscle cramps (n = 21). The graph is a box-and-whisker plot indicating the SF-36 scores (0 100) on each subscale before (empty columns) and 4 months after L-carnitine supplementation (shaded columns). indicates p < 0.05 compared to the value before L-carnitine supplementation, calculated using the Wilcoxon signed rank test. The scores on SF-36 subscale of PF, RP and RE were significantly lower in diabetic patients with diabetic retinopathy. Previous reports showed visual impairment due to diabetic retinopathy has a significant negative impact on patients quality of life [19]. Our results possibly indicate that participants with diabetic retinopathy had lower QOL in addition to those with muscle cramps. To the best of our knowledge, this is the first report of L-carnitine supplementation improving the symptoms and QOL in diabetic patients with muscle cramps. L-carnitine supplementation resulted in a decrease in the frequency of muscle cramps and in Wong-Baker FACES Pain Rating Scale score, and associated with an increase in the scores on the BP, VT, SF, and RE subscales of the SF-36. Several previous studies have also shown that L-carnitine supplementation is commonly utilized in patients with inborn errors of carnitine metabolism and muscular carnitine deficiency [11], hemodialysis patients with muscular symptoms [3], and cirrhosis patients who experience muscle cramps [14]. In another point of view, relief from pain caused by muscle cramps mainly improved the mental health of QOL. We have already mentioned before that the SF-36 comprises eight subscales. In the original American English version, the four subscale (PF, RP, BP and GH) measures are often given the greatest weights to form a physical component [20]. The other four subscales (VT, SF, RE, and MH) are the greatest contributors to a mental component [20]. These two components are conceived as being parts of a higher-order concept of QOL than the eight subscales [21]. In this study, the SF-36 subscales of PF, RP, BP and GH in physical component and VT and SF in the mental component were significantly lower in patients with painful muscle cramps. L-carnitine supplementation was associated with the relief of pain and with an increase in the scores only on the BP in the physical component but the scores in 3 of 4 mental component subscales, VT, RE, and SF, of the SF-36. These findings suggest that the relief of pain from muscle cramps was mainly psychological. The report from Cocito and colleagues also revealed that the mental composite score correlated only with pain and not with the presence of neuropathy [16]. A study by Sabatowski et al. revealed that pregabalin treatment of post-herpetic neuralgia significantly improved pain and the scores on the BP, VT, and MH subscales of the SF-36 [22]. Our study has some limitations. First, this was a single center study. Second, patient allocation was not randomized or double-blinded because the attending physician prescribed L-carnitine supplementation according to the patients wishes. The current study did not have a control group, and it is difficult to disprove a placebo effect. Third, the sample size was small and four participants dropped out because they could not financially afford the L-carnitine supplementation. More studies, such as interventional trials with a larger sample size, are needed to
6 6 Imbe et al. confirm the current these findings. In conclusion, our findings indicate muscle cramps decrease the QOL in patients with diabetes, and that L-carnitine supplementation alleviates muscle cramps and improves the QOL in diabetic patients with muscle cramps. Thus, clinicians should consider L-carnitine supplementation in diabetic patients with muscle cramps. Disclosure None of the authors have any potential conflicts of interest associated with this research. References 1. Katzberg HD (2015) Neurogenic muscle cramps. J Neurol 262: Nakanishi H, Kurosaki M, Tsuchiya K, Nakakuki N, Takada H, et al. (2015) L-carnitine reduces muscle cramps in patients with cirrhosis. Clin Gastroenterol Hepatol 13: Sakurauchi Y, Matsumoto Y, Shinzato T, Takai I, Nakamura Y, et al. (1998) Effects of L-carnitine supplementation on muscular symptoms in hemodialyzed patients. Am J Kidney Dis 32: Katzberg H, Kokokyi S, Halpern E, Lovblom E, Barnett C, et al. (2014) Prevalence of muscle cramps in patients with diabetes. Diabetes Care 37: e17 e Davies M, Brophy S, Williams R, Taylor A (2006) The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 29: Fukuhara S, Suzukamo Y (2004) Manual of SF-36v2 Japanese version. Institute for Health Outcomes & Process Evaluation research, Kyoto (In Japanese). 7. Tapp RJ, Dunstan DW, Phillips P, Tonkin A, Zimmet PZ, et al. (2006) Association between impaired glucose metabolism and quality of life: results from the Australian diabetes obesity and lifestyle study. Diabetes Res Clin Pract 74: Kamarul Imran M, Ismail AA, Naing L, Wan Mohamad WB (2010) Type 2 diabetes mellitus patients with poor glycaemic control have lower quality of life scores as measured by the Short Form-36. Singapore Med J 51: Fukuhara S, Ware JE Jr, Kosinski M, Wada S, Gandek B (1998) Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 51: Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K (1998) Translation, adaptation, and validation of the SF-36 health survey for use in Japan. J Clin Epidemiol 51: Dambrova M, Liepinsh E (2015) Risks and benefits of carnitine supplementation in diabetes. Exp Clin Endocrinol Diabetes 123: Poorabbas A, Fallah F, Bagdadchi J, Mahdavi R, Aliasgarzadeh A, et al. (2007) Determination of free L-carnitine levels in type II diabetic women with and without complications. Eur J Clin Nutr 61: Li S, Li Q, Li Y, Li L, Tian H, et al. (2015) Acetyl-Lcarnitine in the treatment of peripheral neuropathic pain: a systematic review and meta-analysis of randomized controlled trials. PLoS One 10: e Chatrath H, Liangpunsakul S, Ghabril M, Otte J, Chalasani N, et al. (2012) Prevalence and morbidity associated with muscle cramps in patients with cirrhosis. Am J Med 125: Benbow SJ, Wallymahmed ME, MacFarlane IA (1998) Diabetic peripheral neuropathy and quality of life. QJM 91: Cocito D, Paolasso I, Pazzaglia C, Tavella A, Poglio F, et al. (2006) Pain affects the quality of life of neuropathic patients. Neurol Sci 27: Dermanovic Dobrota V, Hrabac P, Skegro D, Smiljanic R, Dobrota S (2014) The impact of neuropathic pain and other comorbidities on the quality of life in patients with diabetes. Health Qual Life Outcomes 12: Currie CJ, Poole CD, Woehl A, Morgan CL, Cawley S, et al. (2006) The health-related utility and health-related quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy. Diabetologia 49: Brown GC (1999) Vision and quality-of-life. Trans Am Ophthalmol Soc 97: McHorney CA, Ware JE Jr, Raczek AE (1993) The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31: Keller SD, Ware JE Jr, Bentler PM, Aaronson NK, Alonso J, et al. (1998) Use of structural equation modeling to test the construct validity of the SF-36 health survey in ten countries: results from the IQOLA Project. J Clin Epidemiol 51: Sabatowski R, Galvez R, Cherry DA, Jacquot F, Vincent E, et al. (2004) Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 109:
PREVALENCE AND IMPACT OF PERIPHERAL NEUROPATHY ON QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS: PILOT STUDY
Trakia Journal of Sciences, Vol. 16, Suppl. 1, pp 71-76, 2018 Copyright 2018 Trakia University Available online at: http://www.uni-sz.bg ISSN 1313-3551 (online) doi:10.15547/tjs.2018.s.01.015 PREVALENCE
More informationLiving Donor Liver Transplantation Patients Follow-up : Health-related Quality of Life and Their Relationship with the Donor
Showa Univ J Med Sci 29 1, 9 15, March 2017 Original Living Donor Liver Transplantation Patients Follow-up : Health-related Quality of Life and Their Relationship with the Donor Shinji IRIE Abstract :
More informationDifferences in Emotional Distress among Inpatients with Type 1, Obese Type 2, and Non-Obese Type 2 Diabetes Mellitus
ORIGINAL ARTICLE Differences in Emotional Distress among Inpatients with Type 1, Obese Type 2, and Non-Obese Type 2 Diabetes Mellitus Yoshiko Miyawaki 1, Hiromi Iwahashi 2, Yukiyoshi Okauchi 3, Yoshiko
More informationThe North West Adelaide Health Study
North Diabetes can ruin your day Quality of life after diagnosis Catherine Chittleborough, Patrick Phillips, Maria Drakoulas, Katherine Baldock, Anne Taylor, & the North Team The North Biomedical cohort
More informationPossible discrepancy of HbA1c values and its assessment among patients with chronic renal failure, hemodialysis and other diseases
Clin Exp Nephrol (2015) 19:1179 1183 DOI 10.1007/s10157-015-1110-6 ORIGINAL ARTICLE Possible discrepancy of HbA1c values and its assessment among patients with chronic renal failure, hemodialysis and other
More informationAn evaluation of self-reported oral health and health-related quality of life
J Med Dent Sci 2005; 52: 65 72 Original Article An evaluation of self-reported oral health and health-related quality of life Akiko Shimada 1, Yoshiyuki Sasaki 2 and Shiro Mataki 1 1) Behavioral Dentistry,
More informationKendai Kaneshima 1, Akiyoshi Seshimo 1, Kunitomo Miyake 1, Shingo Kameoka 1, Satoru Shimizu 2
Int Surg 2015;100:1429 1434 DOI: 10.9738/INTSURG-D-14-00263.1 Examination of the Relationship Between Postoperative Quality of Life and Gastric Emptying Function After Pylorus-Preserving Gastrectomy and
More informationAdjustments to amputation and artificial limb, and quality of life in lower limb amputees Sinha, Richa
University of Groningen Adjustments to amputation and artificial limb, and quality of life in lower limb amputees Sinha, Richa IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine. Study Identifiers: NCT
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationCHAPTER - III METHODOLOGY
74 CHAPTER - III METHODOLOGY This study was designed to determine the effectiveness of nurse-led cardiac rehabilitation on adherence and quality of life among patients with heart failure. 3.1. RESEARCH
More informationThe Chinese University of Hong Kong The Nethersole School of Nursing. CADENZA Training Programme
The Chinese University of Hong Kong The Nethersole School of Nursing CTP003 Chronic Disease Management and End-of-life Care Web-based Course for Professional Social and Health Care Workers Copyright 2012
More informationHealth-related quality of life of diabetic foot ulcer patients and their caregivers
Diabetologia (2005) 48: 1906 1910 DOI 10.1007/s00125-005-1856-6 ARTICLE M. H. Nabuurs-Franssen. M. S. P. Huijberts. A. C. Nieuwenhuijzen Kruseman. J. Willems. N. C. Schaper Health-related quality of life
More informationKey words : elderly person, health-related QOL, functional fitness, health promotion
53 137-145 2008 137 12 3 3 3 3 4 Yoichi Nakamura 1),2), Kiyoji Tanaka 3), Noriko Yabushita 3), Tomoaki Matsuo 3), Yoshio Nakata 3) and Yukako Murotake 4) : Aiming for improvement in Health-related QOL
More informationAdvice following an Independent Review Panel (IRP)
Scottish Medicines Consortium Advice following an Independent Review Panel (IRP) Pregabalin 25, 50, 75, 100, 150, 200 and 300mg capsules (Lyrica ) Pfizer No. 157/05 7 July 2006 The Scottish Medicines Consortium
More informationAssessment of health related quality of life in patients with hemifacial spasm
International Journal of Advances in Medicine Singh PK et al. Int J Adv Med. 2016 Nov;3(4):893-897 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20163719
More informationASSESSMENT OF QOL IN PATIENTS WITH PRADER WILLY SYNDROME
ASSESSMENT OF QOL IN PATIENTS WITH PRADER WILLY SYNDROME Aiming at investigating the relationship between QoL and clinical picture in patients with PWS, we conducted a multicentric study with prospective
More informationEfficacy/pharmacodynamics: 85 Safety: 89
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: Sanofi Drug substance:
More informationScottish Medicines Consortium
Scottish Medicines Consortium duloxetine 30mg and 60mg capsules (Cymbalta ) No. (285/06) Eli Lilly and Company Limited/Boehringer Ingelheim 4 August 2006 The Scottish Medicines Consortium has completed
More informationAnalysis for the Improvement of Inadequate Glycemic Control in Patients with Type 2 Diabetes Mellitus in Nagano, Japan
Shinshu Med J, 66⑸:319~324, 2018 Analysis for the Improvement of Inadequate Glycemic Control in Patients with Type 2 Diabetes Mellitus in Nagano, Japan Ai Sato 1 ), Yoshihiko Sato 1)*, Yuki Kobayashi 1)
More informationABSTRACT MATERIALS AND METHODS INTRODUCTION
143 144 EFFECT OF L-CARNITINE ON QOL IN HEMODIALYSIS PATIENTS RESULTS OF A SINGLE BLIND, RANDOMIZED, PLACEBO- CONTROLLED CLINICAL TRIAL TO STUDY THE EFFECT OF INTRAVENOUS L-CARNITINE SUPPLEMENTATION ON
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationNeuropathic Pain Treatment Guidelines
Neuropathic Pain Treatment Guidelines Background Pain is an unpleasant sensory and emotional experience that can have a significant impact on a person s quality of life, general health, psychological health,
More informationImprovement of glycemic control and quality-of-life by insulin lispro therapy: Assessing benefits by ITR-QOL questionnaires
diabetes research and clinical practice 81 (2008) 169 178 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/diabres Improvement of glycemic control and quality-of-life by insulin
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationImpact of Physical Activity on Metabolic Change in Type 2 Diabetes Mellitus Patients
2012 International Conference on Life Science and Engineering IPCBEE vol.45 (2012) (2012) IACSIT Press, Singapore DOI: 10.7763/IPCBEE. 2012. V45. 14 Impact of Physical Activity on Metabolic Change in Type
More informationDMEP Study Section 1 1
DMEP Study Section 1 1 1. EXECUTIVE SUMMARY 1.1 Objectives The specific aims of the Diabetes Mellitus Education Program (DMEP) were to examine the role of the community pharmacist in the disease state
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationStudy on quality of life of chronic kidney disease stage 5 patients on hemodialysis Gyawali M, Paudel HC, Chhetri PK, Shankar PR, Yadav SK
JMCJMS Research article Study on quality of life of chronic kidney disease stage 5 patients on hemodialysis Gyawali M, Paudel HC, Chhetri PK, Shankar PR, Yadav SK JF Institute of Health Science/LACHS Hattiban
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Protein Restriction to prevent the progression of diabetic nephropathy GUIDELINES
Protein Restriction to prevent the progression of diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. A small volume of evidence suggests
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Lyrica / Pregabalin
More informationThe glycated albumin to HbA1c ratio is elevated in patients with fulminant type 1 diabetes mellitus with onset during pregnancy
41 ORIGINAL The glycated albumin to HbA1c ratio is elevated in patients with fulminant type 1 diabetes mellitus with onset during pregnancy Masafumi Koga 1, Ikki Shimizu 2, Jun Murai 3, Hiroshi Saito 3,
More informationEach copy of any part of a JSTOR transmission must contain the same copyright notice that appears on the screen or printed page of such transmission.
Reliability of an Arabic Version of the RAND-36 Health Survey and Its Equivalence to the US- English Version Author(s): Stephen Joel Coons, Saud Abdulaziz Alabdulmohsin, JoLaine R. Draugalis, Ron D. Hays
More informationJong Chul Won, 1 Yong-Jin Im, 2 Ji-Hyun Lee, 3 Chong Hwa Kim, 4 Hyuk Sang Kwon, 5 Bong-Yun Cha, 5 and Tae Sun Park 6. 1.
Hindawi Journal of Diabetes Research Volume 2017, Article ID 5751687, 9 pages https://doi.org/10.1155/2017/5751687 Research Article Clinical Phenotype of Diabetic Peripheral Neuropathy and Relation to
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationLong-Term Care Updates
Long-Term Care Updates January 2019 By Kristina Nikl, PharmD Several recent studies evaluating the management of diabetes in older adults have concluded that 25-52% of elderly patients are currently being
More informationThe World Health Organization (WHO) has described diabetes mellitus as Metabolic
1.1. Background The World Health Organization (WHO) has described diabetes mellitus as Metabolic disorder of multiple etiology characterized by chronic hyperglycemia with disturbances of carbohydrate,
More informationCLINICAL TRIAL. Nobuya Inagaki 1 *,HirokiSano 2,YoshifumiSeki 2, Shingo Kuroda 2, Kohei Kaku 3
Efficacy and safety of once-weekly oral trelagliptin switched from once-daily dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: An open-label, phase 3 exploratory study Nobuya
More informationDiabetic Neuropathy: Discordance between Symptoms and Electrophysiological Testing in Saudi Diabetics
Bahrain Medical Bulletin, Vol.24, No.1, March 2002 Diabetic Neuropathy: Discordance between Symptoms and Electrophysiological Testing in Saudi Diabetics Daad H Akbar, FRCP(UK), Arab Board, Saudi Board
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 12: , 2016
EXPERIMENTAL AND THERAPEUTIC MEDICINE 12: 3353-3358, 2016 Evaluation of the health-related quality of life using the 36-item short form health survey in patients with chronic hepatitis C receiving pegylated
More informationAwareness of Glycosylated Haemoglobin (HbA1c) Among Type 2 Diabetes Mellitus Patients in Hospital Putrajaya
Malaysian Journal of Medicine and Health Sciences (ISSN 1675-8544); Vol. 11 (2) June 2015: 1-8 Awareness of Glycosylated Haemoglobin (HbA1c) Among Type 2 Diabetes Mellitus Patients in Hospital Putrajaya
More informationA Case Series of Burning Mouth Syndrome Treated with Stellate Ganglion Near-Infrared
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 14, Issue 6 Ver. IV (Jun. 2015), PP 39-43 www.iosrjournals.org A Case Series of Burning Mouth Syndrome
More informationValidation of the Russian version of the Quality of Life-Rheumatoid Arthritis Scale (QOL-RA Scale)
Advances in Medical Sciences Vol. 54(1) 2009 pp 27-31 DOI: 10.2478/v10039-009-0012-9 Medical University of Bialystok, Poland Validation of the Russian version of the Quality of Life-Rheumatoid Arthritis
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:
SYNOPSIS Protocol No.: TOPMAT-MIG-303 EudraCT No.: 2005-000321-29 Title of Study: A double-blind, randomised, placebo-controlled, multicentre study to investigate the efficacy and tolerability of in prolonged
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationDiabetes treatment by the algorithm
Diabetes treatment by the algorithm Joseph Dawley, M.D. Southwest Oklahoma Family Medicine Residency Oklahoma University Health Sciences Center Clinical Assistant Professor Objectives By the end of this
More informationSchool of Health Science & Nursing, Wuhan Polytechnic University, Wuhan , China 2. Corresponding author
2017 International Conference on Medical Science and Human Health (MSHH 2017) ISBN: 978-1-60595-472-1 Association of Self-rated Health Status and Perceived Risk Among Chinese Elderly Patients with Type
More informationCOMPARISON OF QUALITY OF LIFE SCORES IN ADOLESCENTS WITH PRIMARY DYSMENORRHEA
Original Article 13 COMPARISON OF QUALITY OF LIFE SCORES IN ADOLESCENTS WITH PRIMARY DYSMENORRHEA Kusuma Sriyakul 1, Somboon Kietinun 2, Junya Pattaraarchachai 2, Nijsiri Ruangrungsi 1,* 1 College of Public
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More informationA reassessment of factor structure of the Short Form Health Survey (SF-36): A comparative approach
A reassessment of factor structure of the Short Form Health Survey (SF-36): A comparative approach Vida Alizad (1) Manouchehr Azkhosh (2) Ali Asgari (3) Karyn Gonano (4) (1) Iranian Research Center on
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine. According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationScottish Medicines Consortium
Scottish Medicines Consortium pregabalin, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg capsules (Lyrica ) No. (389/07) Pfizer Limited 6 July 2007 The Scottish Medicines Consortium has completed
More informationIJBCP International Journal of Basic & Clinical Pharmacology
Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20164105 Original Research Article Assessment of
More informationThe Impact of Musculoskeletal Pain on Health-Related Quality of Life in Fort Prajaksilapakom Hospital
The Impact of Musculoskeletal Pain on Health-Related Quality of Life in Fort Prajaksilapakom Hospital Chanwit Phongamwong MD*, Ariya Mungkumpa BSc**, Wimonsiri Pawapootanon BSc**, Kunlisa Saiyotha BSc**,
More informationQuality of life defined
Psychometric Properties of Quality of Life and Health Related Quality of Life Assessments in People with Multiple Sclerosis Learmonth, Y. C., Hubbard, E. A., McAuley, E. Motl, R. W. Department of Kinesiology
More informationMoving to an A1C-Based Screening & Diagnosis of Diabetes. By Prof.M.Assy Diabetes&Endocrinology unit
Moving to an A1C-Based Screening & Diagnosis of Diabetes By Prof.M.Assy Diabetes&Endocrinology unit is the nonenzymatic glycated product of the hemoglobin beta-chain at the valine terminal residue. Clin
More informationComparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary
Number 14 Effective Health Care Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Background and Key Questions
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER. Volume: Page:
SYNOPSIS Protocol No: OROS-ANA-3001 Title of Study: Randomized, open-label, comparative parallel group study to assess efficacy and safety of flexible dosages of OROS hydromorphone once-daily compared
More informationEVALUATION OF KNOWLEDGE, ATTITUDE AND PRACTICE TOWARDS DIABETES SCREENING AMONG UNIVERSITY FACULTY MEMBERS AND HIGH SCHOOL TEACHERS IN SHIRAZ, IRAN
EVALUATION OF KNOWLEDGE, ATTITUDE AND PRACTICE TOWARDS DIABETES SCREENING AMONG UNIVERSITY FACULTY MEMBERS AND HIGH SCHOOL TEACHERS IN SHIRAZ, IRAN Pegah Jahani 1 and *Gholamreza Abdollahifard 2 1 Student
More informationChanges in quality of life in patients with acromegaly after surgical remission A prospective study using SF-36 questionnaire
2017, 64 (1), 27-38 Original Changes in quality of life in patients with acromegaly after surgical remission A prospective study using SF-36 questionnaire Shingo Fujio 1), Hiroshi Arimura 2), Hirofumi
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2016 Section: DME Place(s)
More informationClinialTrials.gov Identifier: HOE901_4020 Insulin Glargine Date: Study Code: This was a multicenter study that was conducted at 59 US sites
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationAnne M. Calkins, 1 Joseph Shurman, 2 Mark Jaros, 3 Richard Kim, 4 Gwendoline Shang 4. New York Spine and Wellness Center, North Syracuse, NY; 2
Peripheral Edema and Weight Gain in Adult Patients With Painful Diabetic Peripheral Neuropathy Receiving Gabapentin Enacarbil or Pregabalin Enrolled in a Randomized, Phase 2 Trial Anne M. Calkins, 1 Joseph
More informationMusculoskeletal Problems Affect the Quality of Life of Patients with Parkinson s Disease
https://doi.org/10.14802/jmd.18022 / J Mov Disord 2018;11(3):133-138 pissn 2005-940X / eissn 2093-4939 ORIGINAL ARTICLE Musculoskeletal Problems Affect the Quality of Life of Patients with Parkinson s
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationPredictors of postoperative bleeding after vitrectomy for vitreous hemorrhage in patients with diabetic retinopathy
ORIGINAL ARTICLE Predictors of postoperative bleeding after vitrectomy for vitreous hemorrhage in patients with diabetic retinopathy Saori Motoda 1, Nobuhiko Shiraki 2, Takuma Ishihara 3, Hirokazu Sakaguchi
More informationErratum to: Environ Health Prev Med DOI /s Masami Kitaoka 1 Junko Mitoma. Thao Thi Thu Nguyen 1 Toshio Hamagishi
Environ Health Prev Med (2016) 21:215 223 DOI 10.1007/s12199-016-0525-3 ERRATUM Erratum to: The relationship between hypertension and healthrelated quality of life: adjusted by chronic pain, chronic diseases,
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-INT-24 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-INT-24 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral disturbances in demented patients: an international, multicenter,
More informationShohei Omokawa Toshihiko Imaeda Takuya Sawaizumi Toshimitsu Momose Hiroyuki Gotani Yukio Abe Hisao Moritomo Fuminori Kanaya
J Orthop Sci (2012) 17:551 555 DOI 10.1007/s00776-012-0265-1 ORIGINAL ARTICLE Responsiveness of the Japanese version of the patient-rated wrist evaluation (PRWE-J) and physical impairment measurements
More informationdoi: /hepr.12524
bs_bs_banner Hepatology Research 2016; 46: E45 E50 doi: 10.1111/hepr.12524 Original Article Validation of the Japanese version of the Chronic Liver Disease Questionnaire for the assessment of health-related
More informationChapter 37: Exercise Prescription in Patients with Diabetes
Chapter 37: Exercise Prescription in Patients with Diabetes American College of Sports Medicine. (2010). ACSM's resource manual for guidelines for exercise testing and prescription (6th ed.). New York:
More informationSponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationPatients characteristics associated with better glycemic response to teneligliptin and metformin therapy in type 2 diabetes: a retrospective study
International Journal of Advances in Medicine Gadge PV et al. Int J Adv Med. 2018 Apr;5(2):424-428 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20181082
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationMental health changes in African American men following an exercise training study: (ARTIIS) Robert L. Newton, Jr., Ph.D.
Mental health changes in African American men following an exercise training study: (ARTIIS) Robert L. Newton, Jr., Ph.D. Health benefits of exercise Plethora of studies showing mental health benefits
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 4/1/2018 Section: DME Place(s)
More informationDOI: /jemds/2014/2044 ORIGINAL ARTICLE
AN OBSERVATIONAL STUDY COMPARING SITAGLIPTIN TO METFORMIN AS A INITIAL MONOTHERAPY IN TYPE 2 DIABETES MELLITUS PATIENTS Mohd. Riyaz 1, Imran 2, Rinu Manuel 3, Nidhisha K. Joseph 4 HOW TO CITE THIS ARTICLE:
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationMerck & Co, Inc. Announced Approval of JANUVIA TM (INN: sitagliptin), a new oral treatment of diabetes, by the US FDA
October 23, 2006 Ono Pharmaceutical Co., Ltd., Public Relations Phone: +81-6-6263-5670 Banyu Pharmaceutical Co., Ltd., Public Relations Phone: +81-3-6272-1001 Merck & Co, Inc. Announced Approval of JANUVIA
More informationGuideline for antihyperglycaemic therapy in adults with type 2 diabetes
Guideline for antihyperglycaemic therapy in adults with type 2 diabetes Version Control Version Number Date Amendments made 1 January 2018 1.1 February 2018 Amended to reflect updated SPC advice for sitagliptin
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2017 Section: DME Place(s)
More informationSYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve
More informationAkio Ohta, Kaori Arai, Ami Nishine, Yoshiyuki Sada, Hiroyuki Kato, Hisashi Fukuda, Shiko Asai, Yoshio Nagai, Takuyuki Katabami and Yasushi Tanaka
Endocrine Journal 2013, 60 (2), 173-177 Or i g i n a l Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial
More informationOptimizing Postpartum Maternal Health to Prevent Chronic Diseases
Optimizing Postpartum Maternal Health to Prevent Chronic Diseases Amy Loden, MD, FACP, NCMP Disclosures Research: None Financial: none applicable to this presentation PRIUM QEssentials Market Research
More informationChapter 3 - Does Low Well-being Modify the Effects of
Chapter 3 - Does Low Well-being Modify the Effects of PRISMA (Dutch DESMOND), a Structured Selfmanagement-education Program for People with Type 2 Diabetes? Published as: van Vugt M, de Wit M, Bader S,
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationHealth-related quality of life among dialysis patients on three continents: The Dialysis Outcomes and Practice Patterns Study
Kidney International, Vol. 64 (2003), pp. 1903 1910 Health-related quality of life among dialysis patients on three continents: The Dialysis Outcomes and Practice Patterns Study SHUNICHI FUKUHARA, ANTONIO
More informationSkipping Breakfast is Associated with Constipation in Post-Adolescent Female College Students in Japan
Skipping Breakfast is Associated with Constipation in Post-Adolescent Female College Students in Japan 4 Tomoko Fujiwara Faculty of Home Economics, Ashiya College, Ashiya, Japan 1. Introduction Intake
More informationSUPPLEMENTARY DATA. Supplementary Methods
Supplementary Methods Chronic kidney disease stage 4 or 5 Current diabetic foot with ulcer, soft tissue infection or necrosis Unstable angina, myocardial infarction, or cerebrovascular accident over the
More informationWelcome and Introduction
Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for
More informationLongitudinal Assessment of Health-Related Quality of Life (HRQL) of Patients With Multiple Sclerosis
Longitudinal Assessment of Health-Related Quality of Life (HRQL) of Patients With Multiple Sclerosis Wilma M. Hopman, MA; Helen Coo, MSc; Donald G. Brunet, MD; Catherine M. Edgar, BNSc, RN; and Michael
More informationCharacteristics of Sleep Disturbances in Patients with Gastroesophageal Reflux Disease
ORIGINAL ARTICLE Characteristics of Sleep Disturbances in Patients with Gastroesophageal Reflux Disease Narika Iwakura 1, Yasuhiro Fujiwara 1, Masatsugu Shiba 1, Masahiro Ochi 2, Takashi Fukuda 3, Tetsuya
More informationFinal Report. HOS/VA Comparison Project
Final Report HOS/VA Comparison Project Part 2: Tests of Reliability and Validity at the Scale Level for the Medicare HOS MOS -SF-36 and the VA Veterans SF-36 Lewis E. Kazis, Austin F. Lee, Avron Spiro
More informationObesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients
ORIGINAL ARTICLE Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients Yukihiro Bando, Hideo Kanehara, Keiko Aoki, Azusa Hisada, Daisyu Toya, Nobuyoshi Tanaka
More informationIs the standard SF-12 Health Survey valid and equivalent for a Chinese population? Citation Quality Of Life Research, 2005, v. 14 n. 2, p.
Title Is the standard SF-12 Health Survey valid and equivalent for a Chinese population? Author(s) Lam, CLK; Tse, EYY; Gandek, B Citation Quality Of Life Research, 2005, v. 14 n. 2, p. 539-547 Issued Date
More informationijer.skums.ac.ir Health related quality of life in the female-headed households Received: 20/Apr/2015 Accepted: 6/Jul/2015
Original article International Journal of Epidemiologic Research, 2015; 2(4):178-183. ijer.skums.ac.ir Health related quality of life in the female-headed households Yousef Veisani 1,2, Ali Delpisheh 1,2*,
More informationReliability and validity of the International Spinal Cord Injury Basic Pain Data Set items as self-report measures
(2010) 48, 230 238 & 2010 International Society All rights reserved 1362-4393/10 $32.00 www.nature.com/sc ORIGINAL ARTICLE Reliability and validity of the International Injury Basic Pain Data Set items
More information